NRx Pharmaceuticals heads into its May 18 earnings with short sellers making one of their most aggressive moves in the stock all year.
Short interest is the story here. Bears have nearly doubled their position in a month — SI has jumped 77% in 30 days to reach 16.6% of the free float, with almost half that build arriving in the past week alone (up 43%). The borrow market reflects the demand: cost to borrow has risen 28% over the past month to around 9%, and availability is tightening. The ORTEX short score has climbed to 77.1, ranking in the bottom 5th percentile of the universe by that measure — a signal that the data is flagging this as one of the more heavily contested names in the market right now. Against that, the stock has rallied 31% in the past month to $3.28, up another 6.5% on the week. Bulls and bears are clearly not in agreement.
Options positioning tells a different story — and that contrast matters. The put/call ratio is running at 0.18, actually below its 20-day average of 0.16, suggesting call buyers still dominate the options flow. There is no meaningful defensive hedging visible in the options market; the PCR's 52-week range runs as high as 0.53, making the current read look relatively bullish in comparison. That divergence — aggressive short positioning on one side, call-heavy options flow on the other — makes the setup unusually charged heading into the print.
The bull-bear debate turns almost entirely on regulatory and commercial execution. Bulls point to NRXP's NRX-100/101 sequential ketamine regimen for bipolar depression with acute suicidal ideation, a clear path to approval targeted for summer 2026, and a supply tailwind from ongoing sterile IV ketamine shortages in the US market. The company is building a commercial team ahead of what it frames as a first-mover advantage in preservative-free, domestically manufactured ketamine. Bears counter that approval uncertainty is real, pre-revenue biotech financials are strained (the PE and PB multiples are deeply negative), and competition in CNS depression therapy is intensifying. All five analysts covering the stock carry Buy ratings — targets ranging from $25 to $49 against a current price of $3.28 — though the gap between current price and target prices is wide enough to reflect significant execution risk rather than near-term certainty. Ascendiant Capital nudged its target to $49 in late April, and HC Wainwright reiterated at $45 around the same time.
The prior earnings print in late March produced a 36% one-day move and a 20% five-day gain — a reminder of how violently this stock can react to news. Monday's report is therefore less a test of quarterly figures and more a test of whether the company can provide concrete clarity on its approval timeline and commercial readiness — the two variables that have shorts and bulls each pricing in very different outcomes.
See the live data behind this article on ORTEX.
Open NRXP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
